cyrilzakka/clinical-trials huggingface dataset:
Clinical Study of 18F -FAPI-RGD in Renal Tumor

The goal of this observational study is to learn about the value of 18F-FAPI-RGD PET/CT imaging in Renal Tumor. Participants will undergo clinical evaluation and 18F-FAPI-RGD PET/CT examination.

Early detection, accurate diagnosis and staging are the keys to effective treatment of kidney cancer patients.Pathological diagnosis is still the gold standard, but renal perforation is invasive examination, there are certain complications, the most common is bleeding and hematoma, rare renal arteriovenous fistula formation and infection.A non-invasive test with high accuracy is expected.68Ga-FAPI-04 has been reported to be superior to 18F-FDG in the study of bone metastases in RCC patients, and in addition to detecting more metastases than 18F-FDGPET/CT, uptake is 3-4 times higher than 18F-FDG.There are also many literatures reporting that APIPET/CT may be better than 18F-FDGPET/CT in the detection of various malignant tumors, and FAPI targeted imaging is a promising way in the diagnosis and treatment of papillary renal cell carcinoma.

18F-FPPRGD2PET/CT may be a useful tool for monitoring early response to anti-angiogenic therapy in patients with mRCC.18F-FPRGD2PET/CT reliably estimated the expression of integrin αvβ3 in renal tumors, and in clear cell RCC(ccRCC) groups, 18F-FPRGD2PET signal correlated with the expression of integrin αvβ3 in tumor cells.In the papillary RCC(pRCC) group, the signal was correlated with the expression of αvβ3.The expression of integrin αvβ3 in ccRCC cells was significantly higher than that in pRCC cells.These findings are consistent with results obtained with other RGD-based tracers in various cancers.The expression level of integrin αvβ3 in tumor cells is associated with invasiveness and metastasis potential, and quantifying it with PET may contribute to the study of integrin αvβ3 as a prognostic factor.

Heterodimer peptide FAPI-RGD was synthesized from FAPI and RGD.FAPI-RGD is a heterodimeric peptide that targets FAP and αvβ3-integrin receptors, 68Ga-FAPI-RGDPET/CT imaging has been used in clinical imaging studies of patients with various tumors.So, we plan to use 18F-FAPI-RGD PET/CT imaging is used in the diagnosis and treatment of renal cancer, and preliminary experiments have confirmed that this examination has a good imaging effect.

Eligibility Criteria:
Inclusion Criteria:

* Age 18 and above
* No gender difference
* Patients who have been diagnosed with, or are clinically highly suspected of, renal tumors and have had no other treatment within 3 months

Exclusion Criteria:

* Patients with a second primary tumor
* Pregnant or breastfeeding
* Severe liver or kidney disease
* Claustrophobia or other PET/CT scan contraindications
A Multicenter Study on Early Diagnosis of NSTE-ACS Patients Based on Machine Learning Model

Early diagnosis of NSTEMI and UA patients is mainly through the construction of machine learning model.

The patients with NSTEMI and UA were included. After manual labeling, the admiss- ion record characteristics of patients were selected. 75% of the data is used to build the model, and 25% of the data is used to verify the validity of the model. Five classification models of one-dimensional convolution (CNN), naive Bayesian (NB), support vector machine (SVM), random forest (RF) and ensemble learning were constructed to identify and diagnose NSTEMI and UA patients. Multi-fold cross-validation and ROC-AUC curve are used to measure the advantages and disadvantages of the models.

Eligibility Criteria:
Inclusion Criteria:

* Patients were included and excluded strictly according to the diagnostic criteria of Chinese guidelines for diagnosis and treatment of Non-STsegment elevation acute coronary syndrome (2016). The patients were admitted to the hospital with chest pain as the main complaint, and were admitted to the first affiliated Hospital of Xinjiang Medical University and the first affiliated Hospital of Medical College of Shihezi Univ- ersity. the patients were diagnosed as NSTEMI and UA by coronary angiography (age range from 30 to 75 years old).

Exclusion Criteria:

- 1. Patients with STEMI, aortic dissecting aneurysm, pneumothorax and other non-cardiogenic chest pain. 2.Severe hepatorenal failure, primary tumor without surgical treatment, non-severe infection complicated with shock and pregnant women. 3.Previous severe valvular disease, viral myocarditis, pericardial effusion, cardiac pacemaker implantation, cardiogenic shock with serious complications, hypertensive heart disease, various cardiomyopathy, congenital heart disease, etc.

4.Patients with heart disease, AECOPD, lung tumor and hyperthyroidism were diagnosed in the past.
Moderate Alcohol Consumption, Risk of Cardiovascular Disease and Type 2 Diabetes: Influence of Alcohol Oxidation

Moderate alcohol consumption is associated with a decreased risk of cardiovascular disease and type 2 diabetes. The association of alcohol consumption with cardiovascular disease is mediated by a functional polymorphism of alcohol dehydrogenase 1c, but the effect of this polymorphism on alcohol metabolism is only investigated in vitro.

The risk reduction of moderate alcohol consumption for cardiovascular disease is explained largely by an increase of HDL cholesterol, but an increase of adiponectin concentrations after moderate alcohol consumption may also be involved. It seems likely that adiponectin is a mediator for the association of moderate alcohol consumption with type 2 diabetes. The mechanism by which moderate alcohol consumption increases adiponectin concentrations is unknown, but ppar-gamma activation may be involved.

effects of this polymorphism on mediators of this relation are not known. This study therefore investigates the effect of moderate alcohol consumption and the influence of alcohol dehydrogenase 1c polymorphism on ppar-gamma activated gene expression and risk factors of cardiovascular disease and type 2 diabetes.

Objectives :

To investigate the effect of moderate alcohol consumption and influence of genetic variation of ethanol oxidation on:

* PPAR-γ activated gene expression
* Markers of coronary heart disease or type 2 diabetes
* Postprandial changes of HPA-axis activity among 36 postmenopausal women with ADH1C genotype associated with slow or fast alcohol metabolism.

Design : Randomized, controlled, not blinded crossover trial with 1 week wash-out preceding each treatment period

Participants

* Description : Apparently healthy postmenopausal women
* Number : 36

Study substances

* Test substance : White wine (ca. 25 g alcohol/day)
* Reference substance : White grape juice

Study treatments Treatment A: 250 ml white wine daily (ca. 25 g alcohol/day) Treatment B: 250 ml white grape juice daily

Study period

- Duration : two periods of 6 weeks preceded by 1 week wash-out period

Test parameters:

* Adiponectin mRNA expression
* Expression of PPAR-gamma activated genes: CD36, lipoprotein lipase, AP2
* Markers of cardiovascular disease (blood lipid profile, Lp-PLA2 activity, hs-CRP, fibrinogen)
* Markers of type 2 diabetes (adiponectin, adiponectin oligomers, insulin sensitivity)
* Parameters of alcohol oxidation (postprandial: blood alcohol and acetate, acetaldehyde)
* HPA-axis activity (postprandial \& fasting: cortisol, ACTH, testosterone)

Eligibility Criteria:
Inclusion Criteria:

* Healthy women aged 40 to 65 years
* Absence of menstrual period for at least 2 years
* Homozygotes for the ADH1C\*1 or ADH1C\*2 allele of ADH1C I349V polymorphism
* Alcohol consumption ≥ 5 and ≤ 21 units/week

Exclusion Criteria:

* Smoking
* Family history of alcoholism
* History of medical or surgical events that may significantly affect the study outcome, particularly metabolic or endocrine disorders and gastrointestinal disorders
* Recent blood donation
Exer-gaming on Upper Extremity Function and Activities of Daily Living in Sub-acute Stroke Patient.

Stroke is one of the leading cause of death, in adult stroke causes permanent disability. Stoke impact the life of a person significantly including the quality of life of an individual and especially performing the task of daily activities independently. About 50% survival of stroke have daily life activity limitation which is affecting their quality of life. Among stroke patients, 69% experience functional motor disturbance in their upper extremity.

The aim of this study is to evaluate the effect of Exer-gaming by using the Xbox Kinect game system on upper extremity motor functions and the ability to perform ADLs in sub-acute stroke. Various treatment methods are used for the rehabilitation of stroke. This study will be a randomized controlled trial, used to compare the effectiveness of Exer gaming on upper extremity function and activities of daily living in sub-acute stroke patient. Subjects with Sub-acute stroke meeting the predetermined inclusion \& exclusion criteria will be divided into two groups using simple random sampling technique. Pre assessment will be done using FMA \& SIS measurements. Subjects in one group will be treated with Conventional therapy and exer gaming and the other will be treated with conventional therapy and activities training session. Each subject will be received a total 18 treatment sessions, with 3 treatment sessions per week for 6 weeks. Post treatment reading for FMA and SIS will be recorded after the end of treatment session. Recorded values will be analyzed for any change using SPSS.


Eligibility Criteria:
Inclusion Criteria:

* 1) First stroke 2) Patient of sub-acute stroke 3) Both gender 4) Between 45 to 65 years of age 6) Total score of 19 or greater on the Mini-Mental State Examination 7) No problems with auditory or visual functioning.

Exclusion Criteria:

* 1) Patient with global aphasia, and blindness, 2) Taking any prescribed drugs that could potentially affect physical function and balance (such as corticosteroids, antipsychotics or antidepressants) 3) Uncontrolled blood pressure (HTN) 4) Cardiac conditions 5) History of seizure 6) Any intervention other than conventional therapy 7) Refusal to use a video game.
Percutaneous Dilatational Tracheostomy: Ultra-perc Versus Ciaglia Blue Dolphin

The aim of this study is to compare Ultra-perc single stage dilator technique with Ciaglia Blue Dolphin ballon dilatation technique for intubated unweanable ICU patients with respect to procedure difficulties and complications.

The investigators conducted a prospective randomized trial to compare Ultra-perc single stage dilator technique (UP) and Ciaglia Blue Dolphin ballon dilatation technique (CBD) From January 2013 to December 2015.

The investigators compared the two groups as regards Procedure difficulties including difficult dilatation, difficult tube insertion, failed tube insertion, false passage and tracheal stoma over dilatation. and Procedure complications including cardiac arrest, pneumothorax, pneumomediastinum, subcutaneous emphysema, hemorrhage and lung atelectasis.

Eligibility Criteria:
Inclusion Criteria:

* sepsis
* cerebrovascular accidents
* cervical cord injury
* traumatic brain injury
* post arrest and chronic obstructive pulmonary disease

Exclusion Criteria:

* patient or family refusal
* emergency tracheostomy
* distorted abnormal anatomy
* bleeding diathesis
* morbid obesity
* previous tracheostomy
* infected surgical site
* Adult respiratory distress syndrome patients requiring high positive end expiratory pressure and high oxygen demands
Proteomic Analysis on Myopic Children Using Orthokeratology Lenses With Good or Poor Myopic Control

The key objective of the study is to gain an understanding of the biochemical processes that contribute to orthokeratology lenses being more effective in specific individuals compared to others. With this knowledge, we hope to optimize treatment effectiveness in those currently experiencing less favorable outcomes from treatment in the future.

The primary aim is to investigate differences in protein levels in children using orthokeratology lenses with various effects of myopia control.

Hypothesis: There is a significant difference in the expression of molecules in children with various effects of myopia control.


Eligibility Criteria:
Inclusion Criteria:

* Children treated with orthokeratology lenses.
* Children on or above the 95th percentile of myopia growth curves for European children at the time of treatment initiation.
* Treatment and follow-up duration ≥ 6 months.

Exclusion Criteria:

* Current use of eye drops.
* Objective signs of dry eyes on slit-lamp examination.
* Active eye infection.
Awake Pronation for Covid-19 Treatment

Observational studies have shown that prone position (PP) in spontaneously breathing patients, may improve oxygenation in individuals with Acute Respiratory Failure (ARF), due to Covid-19 infection.

None so far have evaluated the clinical efficacy of this approach on the patients' outcomes and in a randomised control fashion

Observational studies have shown that prone position (PP) in spontaneously breathing patients, may improve oxygenation in individuals with Acute Respiratory Failure (ARF), due to Covid-19 infection.

These studies were mainly physiological and reported in a subset of patients a poor tolerance. Indeed most of the beneficial effects on gas exchage disappeared in around 40% of tyhe patients, once the patients regained the supine position.

None so far have evaluated the clinical efficacy of this approach on the patients' outcomes and in a randomised control fashion.

This holds particularly true in those patients affected by mild de-novo ARF (PaO2/FiO2 ratio within the range of 200-300), where any form of respiratory support like Continuous Positive Airways Pressure (CPAP), High Flow Nasal Cannula (HFNC) or Noninvasive ventilation (NIV), may be not yet indicated, especially if the patients are admitted to a regular ward as for the case of Covid-19 pandemics, due to the lack of "protected" beds.

Eligibility Criteria:
Inclusion Criteria:

* confirmed COVID-19 infection using PCR
* Acute Respiratory Failure ( 200 \<PaO2/FiO2 \<300) and respiratory rate \< 30 atti/min
* O2 therapy initiated \<72 hrs
* informed consent

Exclusion Criteria:

* Glasgow Coma Scale (GCS) \< 13
* pH\< 7,45, PaCO2 \>45 mmHg
* need for HFNC, CPAP, NIV or intubation
* hemodynamic instability increase of 80-90 mmHg or reduction of 30-40 mmHg in systolic blood pressure
* severe arrythmia of myocardial infarction
* need for sedation
* intolerance to PP
* pregnancy
* Body mass index (BMI) \> 35 kg/m2.
A Phase I Study of Three Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons With CD4+ Cell Number > 300 Cells/mm3

To examine the safety and tolerance of three doses of oral vesnarinone in HIV-infected patients with CD4 count \> 300 cells/mm3.

Twelve patients per dose level receive vesnarinone at 1 of 3 doses for 12 weeks. At least six patients at a given dose level must have completed 2 weeks of treatment before dose is escalated in subsequent patients.

Eligibility Criteria:
Inclusion Criteria

Concurrent Medication:

Allowed:

* Chemoprophylaxis for Pneumocystis carinii, candida, mycobacteria, and herpes simplex.

Patients must have:

* Asymptomatic HIV infection.
* CD4 count \> 300 cells/mm3.
* No prior AIDS-defining illness or current constitutional symptoms of HIV disease.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

* Current history of cardiac disease, including patients who exhibit long QT syndrome on EKG screening.
* Active malignancy other than cutaneous basal cell carcinoma or in situ carcinoma of the cervix.

Concurrent Medication:

Excluded:

* Antiretroviral agents, including ddI, ddC, and AZT.
* Immunosuppressive agents.
* Investigational HIV drugs/therapies including vaccines.
* Interferon.
* Steroids (other than topical).
* Hematopoietins.
* Megestrol acetate.
* Trimethoprim/sulfamethoxazole in excess of 160 mg trimethoprim and 800 mg sulfamethoxazole thrice weekly.
* Cytotoxic chemotherapy.

Concurrent Treatment:

Excluded:

* Radiation therapy.

Patients with the following prior conditions are excluded:

* Prior history of cardiac disease.
* History of agranulocytosis or severe (grade 3) drug-induced neutropenia or documented abnormalities in granulocyte number or function.

Prior Medication:

Excluded:

* AZT, ddI, and ddC within 14 days prior to study entry.
* Prior cytotoxic chemotherapy.

Prior Treatment:

Excluded:

* Radiation therapy (including electron beam irradiation) within 30 days prior to study entry.

Active illicit drug abuse.
A Feasibility Study of Chinese Herbs to Manage Cancer-related Symptoms in Patients With Advanced NSCLC

The current proposal is a feasibility and acceptability study to establish the necessary groundwork for more detailed investigations into the role of CH in reducing symptoms and improving quality of life in NSCLC patients at the Jewish General Hospital (JGH). A standardized and easily administered form of CH will be used, incorporating a carefully selected combination of herbs designed to alleviate a range of common symptoms suffered by patients with advanced NSCLC.

Patients with advanced NSCLC, in addition to their very poor chances of cure or extended survival, frequently suffer a range of different symptoms related to both their disease and its treatment. As a result there is a pressing need to develop more effective anti-cancer therapies and an imperative to enhance the effects of existing treatments and alleviate symptoms more effectively.

Increasing numbers of patients with cancer are using complementary medicine, including Chinese herbs (CH), and evidence is accumulating from a growing number of laboratory studies and clinical trials, that CH may exert beneficial effects for cancer patients in many ways.

The current proposal is a feasibility and acceptability study to establish the necessary groundwork for more detailed investigations into the role of CH in reducing symptoms and improving quality of life in NSCLC patients at the JGH. A standardized and easily administered form of CH will be used, incorporating a carefully selected combination of herbs designed to alleviate a range of common symptoms suffered by patients with advanced NSCLC.

This is a prospective, longitudinal cohort study of a 6-week clinical intervention with Chinese herbs in advanced (Stage 4) NSCLC patients All the active patients who have histologically or cytologically proven metastatic NSCLC with Eastern Cooperative Oncology Group (ECOG) performance status of 0 -2 will be eligible to participate in the study. Quality of life will be assessed by FACT-L and Edmonton Symptom Assessment System (ESAS) questionnaires. Patient will be instructed to complete a diary each day to confirm adherence to treatment and to indicate the reason(s) that any doses were missed or treatment was stopped.

Eligibility Criteria:
Inclusion Criteria:

* Stages 4
* ECOG performance ≤ 3
* Life expectancy greater than ≥ 3 months

Exclusion Criteria:

* Receiving Tyrosine Kinase Inhibitors (TKI), (Tarceva, Iressa)
* Brain metastases
* Patients or families who do not speak English or French
* Abnormal liver function: Alanine aminotransaminase (ALT) \> 40 U/L, Aspartate aminotransaminase (AST) \> 55 U/L, Alkaline phosphatase (ALP) \> 145 U/L , Bilirubin \> 1.7 umol/L.
* Taking regular anti-convulsants, Coumadin or related anti-coagulant, lithium
* Taking regular immunosuppressive medications: azathioprine (Imuran), basiliximab (Simulect), cyclosporine (Neoral, Sandimmune), daclizumab (Zenapax), muromonab-CD3 (OKT3, Orthoclone OKT3), mycophenolate (CellCept), tacrolimus (FK506, Prograf), sirolimus (Rapamune)
BRAVO: Background Regimen of Raltegravir on Virologic Outcome

This is a retrospective chart review of participants in raltegravir expanded access program and will compare virologic response in regimens not containing a protease inhibitor in the antiretroviral background regimen to regimens containing a protease inhibitor in the background regimen.

EAP charts from patients at the study sites who meet the inclusion criteria will be reviewed and data abstracted. A comparison of the response to treatment by viral load measurement with raltegravir will be compared in patients whose regimens contained a protease inhibitor (PI) with those that did not contain a PI. Other endpoints will also be assessed including percent of patients with viral loads less than 400 copies/ml, less than 50 copies/ ml, CD4 cell changes, consequences of failure of raltegravir and use of predictive parameters such as GSS and PSS.

Eligibility Criteria:
Inclusion Criteria:

* Patients previously enrolled in the MK 0518 EAP are eligible
* Patients not enrolled in the MK 0518 EAP (or other Raltegravir protocols) but who meet the specific EAP protocol entry criteria are eligible:

  * Age \>= 16 years
  * Limited or no treatment options due to resistance or intolerance to multiple antiretroviral regimens, documented resistance to at least one drug in each of the 3 classes of oral ARTs (NRTI, NNRTI, PI) by genotype or phenotype testing, intolerance defined as having had a clinically significant adverse event which in the opinion of the clinician provides a contraindication to the use of any drug in that class iii. Patient did not achieve virologic suppression on ART regimen prior to receipt of raltegravir iv. Patient was clinically stable at time of initiation of raltegravir, eg. clinical status and all chronic medications (except ARTs) unchanged for \>= 2 weeks prior to raltegravir receipt.
* Patient received raltegravir for at least 8 weeks
* Baseline and week 8 or later HIV viral load done and available for review
* Resistance test (either genotypic or phenotypic test) available prior to receipt of raltegravir

Exclusion Criteria:

* Patient did not receive approved raltegravir dose of 400 mg BID for at least 8 weeks.
* Patient chart not available for review.
PREFER (Pacemaker Remote Follow-Up Evaluation and Review)

The purpose of the study is to compare remote pacemaker follow-up to current standard of care follow-up. The study will compare the rate of first diagnosis of clinically actionable events between patients who utilize the Medtronic Carelink® Network (Remote arm) versus patients who are followed via routine office visits augmented by transtelephonic monitoring (TTM)(Control arm).

The Clinically Actionable Events (CAE) were identified based on their relation to other comorbidities that may increase the risk of a serious cardiac event. The defined events are:

1. Atrial Tachycardia/Atrial Fibrillation (AT/AF) episodes of greater than 48 hours defined as two consecutive days in which the device records at least 18 hours of AT/AF per day
2. Ventricular pacing that has increased by 30 percent (relative) since the last device interrogation
3. A sensed ventricular response of greater than 100 beats per minute (BPM) during atrial tachyarrhythmia for at least 20 percent of the time since the previous device interrogation
4. Runs of non-sustained ventricular tachycardia (NSVT) greater than 5 beats
5. New onset of AT/AF among patients with no history of AT/AF
6. Loss of atrial capture
7. Loss of ventricular capture
8. Increase in atrial pacing voltage threshold greater than 1 volt (V)
9. Increase in ventricular pacing voltage threshold greater than 1 volt (V)
10. \& 11. Significant change in atrial or ventricular lead impedance, defined as any of the following:

    1. Less than 200 or greater than 2000 ohms (Ω)
    2. Unstable lead impedance deemed to be clinically actionable
    3. Greater than 50 percent change in lead impedance since last interrogation

12. Elective Replacement Indicator (ERI)/Battery End of Life (EOL) indicators

Eligibility Criteria:
Inclusion Criteria:

* Patient has been previously implanted with a dual-chamber or single-chamber EnPulse®, Kappa 900®, or Adapta® device
* Patient agrees to complete all required follow-up transmissions and in-office visits
* Patient is capable of operating the TTM monitor and Medtronic CareLink monitor

Exclusion Criteria:

* Patient is an immediate candidate for an implantable cardioverter defibrillator (ICD)